Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,317 papers from all fields of science
Search
Sign In
Create Free Account
anti-CD137 monoclonal antibody
Known as:
Anti-4-1BB Monoclonal Antibody
, Immunoglobulin G4, Anti-(Human Receptor 4-1BB) (Human Gamma-Chain), Disulfide with Human Kappa-Chain, Dimer
, URELUMAB
A fully human agonistic monoclonal antibody targeting the CD137 receptor with potential immunostimulatory and antineoplastic activities. Anti-CD137…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
6 relations
Antibody-Dependent Cellular Cytotoxicity
B-Lymphocytes
BMS-663513
Cytotoxic T-Lymphocytes
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract B026: Development of tumor-targeted agonistic Immunomodulators using the DARPin® technology platform
V. Levitsky
,
A. Link
,
Michael T. Stump
,
E. Baur
Convergence of Technology and Cancer…
2019
Corpus ID: 86441645
Background: Antibodies against several agonistic immunomodulatory receptors proved to be highly efficacious in preclinical tumor…
Expand
2017
2017
Comparison of an FAP-targeted, CD137 activating DARPin drug candidate with a non-targeted, CD137 activating antibody in a human PBMC transplanted HT-29 mouse tumor model.
J. Hepp
,
A. Link
,
+16 authors
M. Stumpp
2017
Corpus ID: 86414964
e14626Background: Urelumab (BMS-663513) is a humanized monoclonal antibody binding to CD137 which, upon Fc-clustering, leads to…
Expand
2017
2017
Preclinical development of tumor-infiltrating lymphocyte (TIL) based adoptive cell transfer (ACT) immunotherapy for patients with sarcoma and the potential benefit of anti-CD137 stimulation.
M. Nielsen
,
A. Krarup-Hansen
,
+5 authors
N. Junker
2017
Corpus ID: 80999563
e14545Background: Tumor specific TILs can be in vitro expanded and have the ability to induce complete and durable tumor…
Expand
2016
2016
Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity
F. Souza-Fonseca-Guimaraes
,
S. Blake
,
A. Makkouk
,
C. Chester
,
H. Kohrt
,
M. Smyth
Oncoimmunology
2016
Corpus ID: 22239288
ABSTRACT Studies of sequential anti-CD137/anti-CD20 therapy have previously shown that the efficacy of anti-CD20 was heavily…
Expand
2014
2014
Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS-663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin lymphoma.
C. Chester
,
Serena Chang
,
+12 authors
H. Kohrt
2014
Corpus ID: 79082193
3017 Background: Anti-CD137 antibody was shown in both murine cancer models and in a first-in-human, phase I trial (Sznol et al…
Expand
2014
2014
Abstract PL02-03: Immune modulation for cancer therapy: Assessing antagonists and agonists
J. Wolchok
2014
Corpus ID: 71876543
The past decade has been a period of tremendous progress in the area of cancer immunotherapy. The field has progressed from a…
Expand
2013
2013
A phase Ib, open-label, multicenter study of urelumab (BMS-663513) in combination with rituximab in subjects with relapsed/refractory B-cell malignancies.
H. Kohrt
,
J. Godwin
,
+9 authors
R. Levy
2013
Corpus ID: 74222414
TPS3108 Background: CD137 (4-1BB) is a costimulatory molecule that belongs to the TNF superfamily. It is upregulated on activated…
Expand
2012
2012
A formulation for the anti-4-7-antibody
Willow R Diluzio
,
P. M. Nguyen
,
+6 authors
E. H. Jenkins
2012
Corpus ID: 85872120
Highly Cited
2007
Highly Cited
2007
Combined natural killer T-cell based immunotherapy eradicates established tumors in mice.
M. Teng
,
J. A. Westwood
,
+9 authors
M. Smyth
Cancer Research
2007
Corpus ID: 23893170
A rational monoclonal antibody (mAb)-based antitumor therapy approach has previously been shown to eradicate various established…
Expand
Review
2006
Review
2006
Dual immunoregulatory pathways of 4-1BB signaling
D. Vinay
,
Kiweon Cha
,
B. Kwon
Journal of molecular medicine
2006
Corpus ID: 19491673
It is perhaps rare to encounter among the various immunologically competent receptor–ligand pairs that a single cell surface…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE